Novel C5α-substituted carbapenems enhance <i>Mycobacterium abscessus</i> killing via selective target binding and reduced hydrolysis by Bla_Mab.

ABSTRACT: Mycobacterium abscessus (Mab) poses significant clinical challenges and underscores the urgent need for safer and more effective treatments, including β-lactams. Among currently available carbapenems, imipenem is widely used to treat Mab infections by combining with other antibiotics. Commercial carbapenems share a common scaffold with C2 modifications, whereas this study focuses on novel carbapenem candidates with C5α modifications. We evaluated their antibacterial activity against Mab ATCC 19977 and clinical isolates, as well as their acylation of peptidoglycan target receptors (L,D-transpeptidases [LDTs] and penicillin-binding proteins [PBPs]) and the β-lactamase enzyme Bla_Mab. In vitro studies of two C5α-modified carbapenems, JDB/NA-1-157 a

SUBMITTER: Shin E 

PROVIDER: S-EPMC12326981 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature